Fighting Cancer with Polio
A promising new treatment that uses the polio virus to attack a virulent brain cancer called glioblastoma was recently granted breakthrough therapy designation by the FDA.
A promising new treatment that uses the polio virus to attack a virulent brain cancer called glioblastoma was recently granted breakthrough therapy designation by the FDA.
To receive
The polio virus was chosen by Duke Medicine researchers because it seeks out and attaches to a receptor that’s found on the surface of the cells on nearly every kind of solid tumor. For the study, the polio virus was re-engineered, which involved removing a key genetic sequence and replacing it with a harmless portion of a cold virus.
PVS-RIPO can’t cause paralysis or death because it can’t reproduce in normal cells. However, it can reproduce in cancer cells, where it releases toxins that poison them. By infecting the tumor, the protective measures that normally surround tumors and shields them from the immune system is removed. With this shield out of the way, the immune system can attack and kill the tumor cells.
Essentially, the immune system recognizes tumor cells as polio infection and sets off alarms to attack those cells. The modified polio virus starts the killing the cells, and the immune system mounts an additional attack.
Interestingly, the polio virus treatment also appears to set up the tumor to be more responsive to chemotherapy in patients who previously haven’t seen positive results with chemotherapy.
With breakthrough therapy designation, the second phase of the trial will be expanded to about 40 centers, where hundreds of patients may participate. If all goes well, Duke will be allowed to skip the third phase of the trial and make polio therapy for glioblastoma available to all.
Scientists say they’re looking to see if the polio virus can attack other forms of cancer, including breast, colon, pancreatic, prostate, lung, skin and stomach cancers.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025